pI: 4.4836 |
Length (AA): 676 |
MW (Da): 79801 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: N | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 12 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
440 | 632 | 1ihg (A) | 170 | 365 | 21.00 | 0.0000000042 | 1 | 0.38 | 0.61 |
502 | 621 | 1elw (A) | 2 | 118 | 25.00 | 0.0000000016 | 1 | 0.61 | -1.25 |
489 | 632 | 4j8f (A) | 406 | 550 | 26.00 | 0.016 | 1 | 0.566318 | -0.69 |
502 | 621 | 2fbn (A) | 36 | 171 | 32.00 | 0.06 | 0.94 | 0.552815 | -1.07 |
503 | 616 | 1na3 (A) | 3 | 76 | 43.00 | 0.58 | 0.71 | 0.0589391 | 0.55 |
543 | 634 | 3q49 (B) | 63 | 154 | 18.00 | 0.56 | 0.33 | 0.462895 | -1.47 |
578 | 676 | 4gyw (A) | 354 | 450 | 15.00 | 0.068 | 0.06 | 0.36015 | -1.12 |
589 | 676 | 2pl2 (A) | 122 | 206 | 12.00 | 0.86 | 0.04 | 0.280878 | -0.91 |
52 | 235 | 4uos (A) | 2 | 184 | 13.00 | 0.73 | 0.01 | 0.535146 | -1.55 |
464 | 621 | 1p5q (A) | 252 | 423 | 25.00 | 0.035 | 1 | 0.51169 | -0.53 |
480 | 599 | 2fbn (A) | 36 | 171 | 32.00 | 0.058 | 0.94 | 0.558686 | -1.07 |
481 | 594 | 1na3 (A) | 3 | 76 | 43.00 | 0.56 | 0.71 | 0.0645119 | 0.55 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | merozoite, Male Gametocyte. | PlasmoDB Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, gametocyte, sporozoite, early ring, early trophozoite, late schizont, late trophozoite, Oocyst, Ring, Sporozoite, Female Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 24 hs, early schizont, late ring. | Otto TD PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs. | Otto TD |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Ortholog group members (OG5_128799)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G30480 | tetratricopeptide repeat domain-containing protein |
Babesia bovis | BBOV_IV002190 | hypothetical protein |
Babesia bovis | BBOV_IV002150 | Tetratricopeptide repeat protein 1 (TPR) |
Brugia malayi | Bm1_18850 | TPR Domain containing protein |
Caenorhabditis elegans | CELE_C34B2.5 | Protein C34B2.5 |
Dictyostelium discoideum | DDB_G0283677 | hypothetical protein |
Drosophila melanogaster | Dmel_CG14894 | CG14894 gene product from transcript CG14894-RB |
Echinococcus granulosus | EgrG_001097000 | Tetratricopeptide repeat protein 1 |
Echinococcus multilocularis | EmuJ_001097000 | Tetratricopeptide repeat protein 1 |
Giardia lamblia | GL50803_5949 | Tetratricopeptide repeat protein |
Homo sapiens | ENSG00000113312 | tetratricopeptide repeat domain 1 |
Leishmania braziliensis | LbrM.20.3430 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_343630.1 | TPR repeat, putative |
Leishmania infantum | LinJ.34.3630 | hypothetical protein, conserved |
Leishmania major | LmjF.34.3820 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.33.3820 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_04831 | TPR Domain containing protein |
Mus musculus | ENSMUSG00000041278 | tetratricopeptide repeat domain 1 |
Neospora caninum | NCLIV_063670 | hypothetical protein |
Oryza sativa | 4348950 | Os10g0486900 |
Onchocerca volvulus | OVOC1705 | Tetratricopeptide repeat protein 1 homolog |
Plasmodium berghei | PBANKA_1455300 | tetratricopeptide repeat protein, putative |
Plasmodium falciparum | PF3D7_1241900 | tetratricopeptide repeat protein, putative |
Plasmodium knowlesi | PKNH_1461200 | tetratricopeptide repeat protein, putative |
Plasmodium vivax | PVX_100995 | TPR domain containing protein |
Plasmodium yoelii | PY01491 | similar to tetratricopeptide repeat domain 1, putative |
Schistosoma japonicum | Sjp_0219680 | Tetratricopeptide repeat protein 1, putative |
Schistosoma mansoni | Smp_072970 | tetratricopeptide protein |
Schmidtea mediterranea | mk4.012819.00 | Tetratricopeptide repeat protein 1 |
Schmidtea mediterranea | mk4.010049.00 | Tetratricopeptide repeat protein 1 |
Schmidtea mediterranea | mk4.012384.01 | |
Trypanosoma brucei gambiense | Tbg972.4.730 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.4.920 | TPR repeat, putative |
Trypanosoma congolense | TcIL3000_4_530 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.508257.110 | TPR repeat, putative |
Toxoplasma gondii | TGME49_247000 | tetratricopeptide repeat-containing protein |
Theileria parva | TP03_0434 | hypothetical protein |
Trichomonas vaginalis | TVAG_044480 | heat shock protein 70 (HSP70)-interacting protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.920 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.920 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.920 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.920 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_247000 | Toxoplasma gondii | Probably essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.